Keywords: matrix, gets, who, approval, lopinavir/ritonavir, generic, drugmaker
Matrix gets WHO approval for lopinavir/ritonavir
Article | 02 March 2009
US generic drugmaker Mylan says that Matrix Laboratories, its India-based subsidiary in which it holds a 71.5% controlling interest, received the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
